Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Assets Average (2016 - 2025)

Avalo Therapeutics' Assets Average history spans 11 years, with the latest figure at $120.8 million for Q4 2025.

  • For Q4 2025, Assets Average fell 3.06% year-over-year to $120.8 million; the TTM value through Dec 2025 reached $120.8 million, down 3.06%, while the annual FY2025 figure was $133.6 million, 55.59% up from the prior year.
  • Assets Average reached $120.8 million in Q4 2025 per AVTX's latest filing, down from $125.8 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $144.6 million in Q1 2025 to a low of $25.1 million in Q4 2023.
  • Average Assets Average over 5 years is $76.5 million, with a median of $71.7 million recorded in 2022.
  • Peak YoY movement for Assets Average: plummeted 60.18% in 2022, then skyrocketed 395.77% in 2024.
  • A 5-year view of Assets Average shows it stood at $87.8 million in 2021, then tumbled by 60.18% to $35.0 million in 2022, then dropped by 28.11% to $25.1 million in 2023, then soared by 395.77% to $124.6 million in 2024, then decreased by 3.06% to $120.8 million in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Assets Average are $120.8 million (Q4 2025), $125.8 million (Q3 2025), and $132.6 million (Q2 2025).